The single biggest question hanging over cannabis equities as the new week begins: will expanding breadth hold while macro volatility stays muted, allowing momentum names to extend gains into the week of Aug. 24–28, 2026?

Read the full US brief for 2026-08-23.

The single biggest question heading into the week: will the DEA rescheduling process—post-hearing briefs due August 17—produce enough regulatory clarity to move cannabis equities out of their current rangebound pattern?

Read the full US brief for 2026-08-16.

What’s the market pricing for a regulatory win — or a regulatory delay — after the DEA rescheduling hearing wraps up this week?

Read the full US brief for 2026-08-16.

The single biggest question heading into the week: will the DEA post-hearing schedule around August 17 trigger durable flows into U.S.-facing names, or will macro and narrow breadth keep cannabis equities rangebound?

Read the full US brief for 2026-08-16.

The single biggest question hanging over cannabis equities this week is whether the DEA rescheduling record will produce a concrete policy signal by way of post‑hearing filings and industry reaction, or whether markets will remain rangebound into late summer.

Read the full US brief for 2026-08-16.

The single biggest question heading into the week is whether the DEA rescheduling record will meaningfully shift capital flows into U.S.-exposed names ahead of post-hearing briefs due Monday, August 17.

Read the full US brief for 2026-08-16.

The biggest question for cannabis equities heading into the week: will the DEA rescheduling docket — and the post-hearing filings due next week — create a concrete policy catalyst or just another headline that leaves the group rangebound?

Read the full US brief for 2026-08-16.

The single biggest question hanging over cannabis equities this week is whether the DEA rescheduling record — with post-hearing briefs due Aug. 17 — produces any actionable signal about timing for a final administrative decision.

Read the full US brief for 2026-08-16.

The single biggest question for cannabis equities this week: will the DEA rescheduling record — and its immediate post-hearing filings due August 17 — create a near-term directional catalyst, or will the market treat the submissions as noise and stay rangebound?

Read the full US brief for 2026-08-16.

The single biggest question as the new week begins: will next-week headlines on U.S. rescheduling and a handful of idiosyncratic corporate moves finally break the sector’s rangebound trading?

Read the full US brief for 2026-08-16.